Metabolic interactions between prokinetic agents domperidone and erythromycin: An in vitro analysis

Xenobiotica

Volumn 39, Issue 10, 2009, Pages 749-756

  Ung, D ^a   Parkman, H P ^b   Nagar, S ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A4; Domperidone; Erythromycin; Gastroparesis; Mechanism based inhibition

Indexed keywords

CYTOCHROME P450 3A4; DOMPERIDONE; ERYTHROMYCIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME;

CYTOCHROME P-450 CYP3A; DOMPERIDONE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; ERYTHROMYCIN; GASTROINTESTINAL AGENTS; HUMANS; KINETICS; MICROSOMES, LIVER; RECOMBINANT PROTEINS;

EID: 70350642131     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250903096121     Document Type: Article

References (24)

1. Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, Hasler WL, McCallum RW, Olden KW, Parkman HP, Parrish CR, Prather CM, Softer EE, Twillman R, Vinik AI. (2006). Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 18(4):263-283
2. Ahmad N, Keith-Ferris J, Gooden E, Abell T. (2006). Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 6(6):571-576
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815-832
4. Dresser GK, Spence JD, Bailey DG. (2000). Pharmacokinetic pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1):41-57.
5. Friedenberg FK, Parkman HP. (2007). Advances in the management of gastroparesis. Curr Treat Options Gastroenterol 10(4):283-293
6. Galetin A, Burt H, Gibbons L, Houston JB. (2006). Prediction of timedependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34(1):166-175
7. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. (2006). A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7(3):315-334
8. Ishii K, Saito Y, Itai S, Nemoto M, Takayama K, Nagai T. (1998). Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. Drug Dev Ind Pharm 24(2):129-137
9. McCallum RW, Brown RL. (1998). Diabetic and nondiabetic gastroparesis. Curr Treat Options Gastroenterol 1(1):1-7.
10. Michaud V, Simard C, Turgeon J. (2007). An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies. J Chromatogr B Analyt Technol Biomed Life Sci 852(1-2):611-616
11. Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanismbased inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35(2):246-255 (Pubitemid 46148737)
12. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316(1):336-348
13. Pasricha PJ. (2001). Prokinetic agents, antiemetics, and agents used in irritable bowel syndrome. In: Hardman J, Limbird L, Goodman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York, NY: McGraw-Hill.
14. Polasek TM, Miners JO. (2006). Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 62(3):203-208
15. Reddymasu SC, Soykan I, McCallum RW. (2007). Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 102(9):2036-2045
16. Silverman RB. (1995). Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283
17. Simard C, Michaud V, Gibbs B, Masse R, Lessard E, Turgeon J. (2004). Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 34(11-12):1013-1023
18. Smith DS, Ferris CD. (2003). Current concepts in diabetic gastroparesis. Drugs 63(13):1339-1358
19. Thummel KE, Shen DD. (2001). Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman J, Limbird L, Goodman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York, NY: McGraw Hill.
20. Wang YH, Jones DR, Hall SD. (2004). Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32(2):259-266
21. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. (2004). Characterization of human cytochrome P450 enzymes catalysing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58(3):277-287
22. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44(3):279-304.
23. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29(6):687-710.
24. Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9(4):310-322